Vivanza Biosciences Q1 FY27 Results Revenue 914L PAT 14.51L

Pat Growth 25pctResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.0%Reaction day

₹1.89

prior close

₹1.89

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.0%-0.0% vs market

Pharmaceuticals peers, median of 167sector+0.3%-0.3% vs sector

On the reaction day the stock moved in line with Nifty Microcap 250 and 0.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.0+0.0-0.0+0.3-0.3

Next day

-0.5-0.0-0.5+0.7-1.2

-0.5-0.2-0.3+0.6-1.1

+0.5+0.2+0.4+0.2+0.3

+5.3+0.3+5.0+1.2+4.1

+0.5+0.4+0.1+0.2+0.4

-6.3+0.9-7.3+0.2-6.6

15d

-8.5+1.6-10.0+1.4-9.8

-8.5+2.0-10.5+2.4-10.9

-7.9+0.6-8.5+1.8-9.7

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 167Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved unaudited Q1 FY27 results (quarter ended 30 June 2026). Standalone revenue from operations rose to 914.09 lakhs from 782.06 lakhs YoY, with total income at 951.37 lakhs. Profit after tax surged to 14.51 lakhs from 1.86 lakhs in Q1 FY26, recovering from a loss of 26.61 lakhs in Q4 FY26. EPS stood at 0.04 versus a negative 0.07 prior quarter. Limited review report by Shivam Soni and Co is clean with no qualifications or adverse remarks.

Likely market impact

Strong sequential turnaround from loss to profit with rising revenue and clean audit; positive for shareholder sentiment.